Ultragenyx Pharmaceutical Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $369.0 million, 55% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
730
|
673
|
560
|
434
|
363
|
351
|
271
|
104
|
51
|
3
|
—
|
| Product |
408
+20.5%
share 55.9%
|
369
+29.5%
share 54.8%
|
285
+58.3%
share 50.9%
|
180
+51.4%
share 41.5%
|
119
+54.4%
share 32.7%
|
77
+98.9%
share 21.9%
|
39
+91.5%
share 14.3%
|
20
+106.3%
share 19.5%
|
10
+1959.2%
share 19.0%
|
0
share 18.2%
|
—
|
| Royalty |
322
+10.2%
share 44.1%
|
304
+10.5%
share 45.2%
|
275
+50.3%
share 49.1%
|
183
+743.6%
share 42.2%
|
22
+20.8%
share 6.0%
|
18
+38.1%
share 5.1%
|
13
share 4.8%
|
—
|
—
|
—
|
—
|
| Collaboration And License |
—
|
—
|
—
|
71
-68.1%
share 16.4%
|
223
-13.2%
share 61.3%
|
256
+16.9%
share 73.0%
|
219
+162.7%
share 80.9%
|
83
+100.3%
share 80.5%
|
42
+1851.9%
share 81.0%
|
2
share 81.8%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1515673
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.